Competitive Landscape for Epilepsy Examined in New GlobalData Report Now Available at MarketPublishers.com
11 Mar 2013 • by Natalie Aster
LONDON – The global epilepsy market is predicted to grow to about USD 8.1 billion by 2014 and to reach USD 9 billion by 2017, showing a moderate annual increase of around 0.4%. The therapeutics sector is expected to be worth almost USD 4 billion in late 2017, growing at CAGR of 3.5%. The competition among the companies involved in the market is expected lead to the decrease in prices and sales of branded drugs. The usage of second-generation drugs is amid the main factors that spur the growth of global epilepsy market.
UCB, Eisai, Pfizer, GlaxoSmithKline, Novartis, Abbott, Dainippon Sumitomo Pharma are amid the most prominent participants in the global epilepsy market.
New report “PharmaPoint: Epilepsy - Current and Future Players” developed by GlobalData is dedicated to the companies involved in the global epilepsy market. The research study comprises valuable data on the key players of the epilepsy market including their business description, financial overview and SWOT analysis. Examination of the market trends, challenges and factors influencing the market is on hand in the research study. Data on new market entrants can be found in the report too. Besides, the possible future prospects for the market active are also reviewed in the research study.
PharmaPoint: Epilepsy - Current and Future Players
Published: February, 2013
Price: US$ 2,955.00
More insightful market research reports by the publisher can be found at GlobalData page.